David Zawitz Biography and Net Worth

Prior to joining Verrica, Mr. Zawitz served as Executive Vice President and Secretary of PBM Capital Group, LLC since March 2021 after serving in roles of increasing responsibility within PBM Capital’s legal department beginning in 2018. Prior to joining PBM Capital, Mr. Zawitz served in roles of increasing responsibility with CarMax, Inc. from 2012 to 2018, including most recently as Assistant General Counsel and Assistant Secretary, and was an attorney in private practice with Bingham McCutchen LLP from 2010 to 2012 and McKee Nelson LLP from 2007 to 2009. Mr. Zawitz earned a B.S.C. in Commerce with concentrations in Finance and Information Technology from the University of Virginia and a J.D. from the University of Virginia School of Law. He is also a CFA^® charter holder.

What is David Zawitz's net worth?: The estimated net worth of David Zawitz is at least $97.65 thousand as of November 25th, 2025. Zawitz owns 21,000 shares of Verrica Pharmaceuticals stock worth more than $97,650 as of September 17th. This net worth estimate does not reflect any other investments that Zawitz may own. Learn More about David Zawitz's net worth.
How do I contact David Zawitz?: The corporate mailing address for Zawitz and other Verrica Pharmaceuticals executives is 44 West Gay Street, Suite 400, West Chester, PA. Verrica Pharmaceuticals can also be reached via phone at (484) 453-3300 and via email at [email protected]. Learn More on David Zawitz's contact information.
Has David Zawitz been buying or selling shares of Verrica Pharmaceuticals?: David Zawitz has not been actively trading shares of Verrica Pharmaceuticals within the last three months. Most recently, on Tuesday, November 25th, David Zawitz bought 10,000 shares of Verrica Pharmaceuticals stock. The stock was acquired at an average cost of $4.24 per share, with a total value of $42,400.00. Following the completion of the transaction, the chief operating officer now directly owns 21,000 shares of the company's stock, valued at $89,040. Learn More on David Zawitz's trading history.
Who are Verrica Pharmaceuticals' active insiders?: Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), Jayson Rieger (CEO), Ted White (CEO), and David Zawitz (COO). Learn More on Verrica Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Verrica Pharmaceuticals?: During the last year, Verrica Pharmaceuticals insiders bought shares 9 times. They purchased a total of 4,247,576 shares worth more than $18,017,266.64. The most recent insider tranaction occured on August, 18th when CMO Noah L Rosenberg bought 2,030 shares worth more than $9,987.60. Insiders at Verrica Pharmaceuticals own 52.9% of the company. Learn More about insider trades at Verrica Pharmaceuticals.
Information on this page was last updated on 8/18/2026.

David Zawitz Insider Trading History at Verrica Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/25/2025	Buy	10,000	$4.24	$42,400.00	21,000

David Zawitz Buying and Selling Activity at Verrica Pharmaceuticals

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $4.65

$4.57

$4.79

50 Day Range

MA: $5.25

$4.53

$6.53

2 Week Range

Now: $4.65

$3.28

$9.82

Volume

41,303 shs

Average Volume

93,453 shs

Market Capitalization

$79.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49